Horizon Discovery launches new immuno-oncology platform

15 April 2016
2019_biotech_test_vial_discovery_big

Horizon Discovery Group (LSE: HZD), a UK-based biotech specializing in gene editing, announced the launch of a new platform for immuno-oncology on Friday.

The platform consists of several high-throughput assays which are expected to enable researchers to test thousands of potential anti-cancer drugs that recruit the body’s own immune system to fight the disease.

Researchers will be able to study how new drugs are able to activate different types of immune cells as well as increase their ability to kill tumors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology